Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study.
Daniel ShepshelovichDafna YahavRonen Ben AmiHadar GoldvaserNoam TauPublished in: The Journal of antimicrobial chemotherapy (2021)
The results of most non-randomized studies reporting survival benefit of potential anti-COVID-19 drugs were not replicated by large RCTs. Regulators and healthcare professionals should exercise caution and resist the pressure to approve and prescribe drugs of unproven efficacy and potential toxicity to optimize patient care and maintain public trust in medical science.
Keyphrases
- double blind
- open label
- clinical trial
- phase iii
- placebo controlled
- phase ii
- coronavirus disease
- sars cov
- healthcare
- physical activity
- public health
- high intensity
- oxidative stress
- randomized controlled trial
- mental health
- emergency department
- risk factors
- study protocol
- respiratory syndrome coronavirus
- social media
- human health
- climate change
- health information
- resistance training